BioSpace News Archive

KemPharm, Inc. today announced that the Company has completed its analysis of the full data set from its Phase 1 clinical trial exploring the safety and pharmacokinetics (PK) of serdexmethylphenidate (SDX) delivered at doses higher than those previously studied.

XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

Natera, Inc. today announced new Signatera data from the prospective, multi-center CIRCULATE-Japan trial, presented by Dr. Eiji Oki of Kyushu University in an oral presentation at the Society of Surgical Oncology (SSO) 2022 International Conference on Surgical Cancer Care.

Replimune Group Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced that members of its executive team and Key Opinion Leaders will host an investor event to present updated data from the completed cohorts of the Phase 2 IGNYTE clinical trial in non-melanoma skin cancer and melanoma.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), today announced the company has achieved its enrollment target of 40 patients in the EXP-6 cohort of the phase 1/2 registrational TRIDENT-1 study. EXP-6 is comprised of NTRK-positive TKI-pretreated advanced solid tumor patients.

Lexicon Pharmaceuticals, Inc. announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial will be presented as a late-breaker at the American College of Cardiology’s 71st Annual Scientific Session.

Assembly Biosciences, Inc. will host a webcast on Thursday, March 31, 2022 from 8:00 – 9:00 am PT/11:00 am – 12:00 pm ET to introduce its new research program focused on a novel, orally bioavailable small-molecule approach to inhibit entry of HBV and hepatitis delta virus (HDV).

Smith+Nephew, the global medical technology business, announces it will showcase its latest Sports Medicine innovations for joint repair and arthroscopic enabling technologies during the American Academy of Orthopaedic Surgeons 2022 Annual Meeting being held in Chicago, IL.

Kazia Therapeutics Limited, a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences.

BD, a leading global medical technology company, provided additional details related to the planned spinoff of Embecta Corp..